Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in Vivo, Supporting Potential for Broadly Protective Pan-Beta Coronavirus & Variant Vaccine; Supportive Preclinical Data Presented at World Vaccine & Immunotherapy Congress 2021

On December 2, 2021, Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced new preclinical data from its exoVACC™ exosome-based vaccine platform. The data describe for the first time the potential of Codiak’s novel vaccine candidate for SARS-CoV-2, the virus that causes COVID-19, to generate a comprehensive immune response conferring both antibody and T cell-mediated immunity. The study reported the generation of a neutralizing antibody response that showed evidence of activity against multiple SARS-CoV-2 variants. In addition, the ability of exoVACC to generate antigen-specific T cell responses against structurally conserved regions of multiple coronavirus variants provides evidence of a broad immune response to the candidate. The results were presented on December 2, 2021 at the World Vaccine & Immunotherapy Congress (WVIC) 2021 in San Diego.

Login Or Register To Read Full Story